Cargando…

Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

BACKGROUND: To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for advanced endometrial cancer. METHODS: We conducted a retrospective analysis of patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochet, Nathalie, Kahn, Rachel S, Niemierko, Andrzej, Delaney, Thomas F, Russell, Anthony H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842773/
https://www.ncbi.nlm.nih.gov/pubmed/24125168
http://dx.doi.org/10.1186/1748-717X-8-236
_version_ 1782292986350010368
author Rochet, Nathalie
Kahn, Rachel S
Niemierko, Andrzej
Delaney, Thomas F
Russell, Anthony H
author_facet Rochet, Nathalie
Kahn, Rachel S
Niemierko, Andrzej
Delaney, Thomas F
Russell, Anthony H
author_sort Rochet, Nathalie
collection PubMed
description BACKGROUND: To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for advanced endometrial cancer. METHODS: We conducted a retrospective analysis of patients treated at our institution from 2000 to 2011. Inclusion criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine abdomen-confined disease, treated with WAI as part of multimodal therapy. Endpoints were feasibility, acute toxicity, late effects, recurrence-free survival (RFS) and overall survival (OS). Twenty patients were identified. Chemotherapy consisted of 3 to 6 cycles of a platinum-paclitaxel regimen in 18 patients. WAI was delivered using conventional technique to a median total dose of 27.5 Gy. RESULTS: No grade 4 toxicities occurred during chemotherapy or radiotherapy. No radiation dose reduction was necessary. Three patients developed small bowel obstruction, all in the context of recurrent intraperitoneal disease. Kaplan-Meier estimates and 95% confidence intervals for RFS and OS at one year were 63% (38–80%) and 83% (56-94%) and at 3 years 57% (33-76%) and 62% (34-81%), respectively. On univariate Cox analysis, stage IVB and serous papillary (SP) histology were found to be statistically significantly (at the p = 0.05 level) associated with worse RFS and OS. The peritoneal cavity was the most frequent site of initial failure. CONCLUSIONS: Consolidative WAI following chemotherapy is feasible and can be performed without interruption with manageable acute and late toxicity. Patients with endometrioid adenocarcinoma, especially stage FIGO III, had favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in selected patients. Patients with SP do poorly and do not routinely benefit from this approach.
format Online
Article
Text
id pubmed-3842773
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38427732013-11-29 Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes Rochet, Nathalie Kahn, Rachel S Niemierko, Andrzej Delaney, Thomas F Russell, Anthony H Radiat Oncol Research BACKGROUND: To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for advanced endometrial cancer. METHODS: We conducted a retrospective analysis of patients treated at our institution from 2000 to 2011. Inclusion criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine abdomen-confined disease, treated with WAI as part of multimodal therapy. Endpoints were feasibility, acute toxicity, late effects, recurrence-free survival (RFS) and overall survival (OS). Twenty patients were identified. Chemotherapy consisted of 3 to 6 cycles of a platinum-paclitaxel regimen in 18 patients. WAI was delivered using conventional technique to a median total dose of 27.5 Gy. RESULTS: No grade 4 toxicities occurred during chemotherapy or radiotherapy. No radiation dose reduction was necessary. Three patients developed small bowel obstruction, all in the context of recurrent intraperitoneal disease. Kaplan-Meier estimates and 95% confidence intervals for RFS and OS at one year were 63% (38–80%) and 83% (56-94%) and at 3 years 57% (33-76%) and 62% (34-81%), respectively. On univariate Cox analysis, stage IVB and serous papillary (SP) histology were found to be statistically significantly (at the p = 0.05 level) associated with worse RFS and OS. The peritoneal cavity was the most frequent site of initial failure. CONCLUSIONS: Consolidative WAI following chemotherapy is feasible and can be performed without interruption with manageable acute and late toxicity. Patients with endometrioid adenocarcinoma, especially stage FIGO III, had favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in selected patients. Patients with SP do poorly and do not routinely benefit from this approach. BioMed Central 2013-10-14 /pmc/articles/PMC3842773/ /pubmed/24125168 http://dx.doi.org/10.1186/1748-717X-8-236 Text en Copyright © 2013 Rochet et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rochet, Nathalie
Kahn, Rachel S
Niemierko, Andrzej
Delaney, Thomas F
Russell, Anthony H
Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title_full Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title_fullStr Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title_full_unstemmed Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title_short Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
title_sort consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842773/
https://www.ncbi.nlm.nih.gov/pubmed/24125168
http://dx.doi.org/10.1186/1748-717X-8-236
work_keys_str_mv AT rochetnathalie consolidationwholeabdomenirradiationfollowingadjuvantcarboplatinpaclitaxelbasedchemotherapyforadvanceduterineepithelialcancerfeasibilitytoxicityandoutcomes
AT kahnrachels consolidationwholeabdomenirradiationfollowingadjuvantcarboplatinpaclitaxelbasedchemotherapyforadvanceduterineepithelialcancerfeasibilitytoxicityandoutcomes
AT niemierkoandrzej consolidationwholeabdomenirradiationfollowingadjuvantcarboplatinpaclitaxelbasedchemotherapyforadvanceduterineepithelialcancerfeasibilitytoxicityandoutcomes
AT delaneythomasf consolidationwholeabdomenirradiationfollowingadjuvantcarboplatinpaclitaxelbasedchemotherapyforadvanceduterineepithelialcancerfeasibilitytoxicityandoutcomes
AT russellanthonyh consolidationwholeabdomenirradiationfollowingadjuvantcarboplatinpaclitaxelbasedchemotherapyforadvanceduterineepithelialcancerfeasibilitytoxicityandoutcomes